Open access
Oct 2026
Sustained low disease activity during long-term mepolizumab treatment in FIP1L1::PDGFRA-negative hypereosinophilic syndrome: a multicenter real-world study.
Mepolizumab provided sustained long-term disease control with low glucocorticoid exposure in FIP1L1::PDGFRA-negative HES and EoLDAS offers a pragmatic measure of longitudinal disease control that warrants prospective validation and may inform future treat-to-target strategies.
K. Chevalier, François Barde, S. Faguer et al.
· Journal of Allergy and Clini... · 0 citations